ngsova | 1030

NGS Ovarian cancer

Keywords

ARID1A, ATM, ATR, BARD1, BLM, BRAF, BRCA1, BRCA2, BRCAness, BRIP1, CCNE1, CDH1, CDK12, CHEK1, CHEK2, CTNNB1, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, Genomic Instability Score, GIS, Homologous Recombination Deficiency, HRD, HRR, KRAS, MLH1, MRE11, MSH2, MSH3, MSH6, MyChoice, Myriad, NBN, Next Generation Sequencing, NF1, NTRK3, ovarian, Ovary, PALB2, PARP1, PIK3CA, PMS2, POLD1, POLE, PPP2R2A, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD52, RAD54L, RET, STK11, TP53

Material

Tissue biopsy
Tube sterile, white (32)

Note

Complete gene sequencing of HRR-associated genes at the DNA level, including BRCA1, BRCA2, PALB2, and 47 additional genes, including Genomic Instability Score (GIS) (TruSight Oncology 500 HRD powered by Myriad) | There is a possibility of excess information occurring with this analysis. This will be communicated, unless it is noted otherwise when placing the order. Since, in rare cases, findings may also indicate hereditary changes, the Federal Act on Human Genetic Testing (HGTA) requires that patients be appropriately informed (see www.viollier.ch/consent_ssmg). The consent form is intended for internal documentation within the practice and does not need to be submitted to Viollier. Billing: in accordance with TARDOC.

Duration

10 days

Frequency

1 x per week

Method

Next Generation Sequencing, LDT

Price

CHF 0.00

Tariff

0.00 TP

Team of consultants

Dr. med. Katharina Marston FMH Pathology, molecular pathology	FMH Pathology, molecular pathology	T +41 61 486 10 34
Dr. rer. nat. Henriette Kurth FAMH Specialist in laboratory medicine, medical genetics	FAMH Specialist in laboratory medicine, medical genetics	T +41 61 486 14 78
Dr. med. Jean-François Egger FMH pathology	FMH pathology	T +41 22 789 63 63
PD Dr. med. Andreas Zettl FMH pathology, molecular pathology	FMH pathology, molecular pathology	T +41 61 486 10 12
Dr. med. Santiago Giménez de Mestral FMH pathology, cytopathology	FMH pathology, cytopathology	T +41 22 789 63 36